Skip to content
Screener

uniQure QURE Cash & Equivalents

Cash & Equivalents at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$571.15M+11.9%
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
$276.58M+137%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$833.99M-43.7%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
$12.77M-6.6%
Candel Therapeutics, Inc. logo
Candel Therapeutics, Inc.CADL
$194.83M+111%
Regenxbio logo
RegenxbioRGNX
$36.49M-54.1%

Other financials

Income statement

See full
Revenue$5.8M+11.0%
Gross profit$5.5M+19.2%
Operating income-$52.2M-19.0%
Net income-$81.1M-115%
EPS (diluted)-$1.22-76.8%

Balance sheet

See full
Total debt$62.8M-5.8%
Total equity$324.1M+8,195%
Total assets$985.1M+68.4%

Cash flow

See full
Operating cash flow-$28.6M+28.4%
CapEx$472.0K+81.5%
Free cash flow-$29.0M+27.7%

Valuation

See full
Market cap$3.15B+325%
Enterprise value$2.8B+406%
P/S168.5×+117×

Profitability

See full
Gross margin92.5%+4.6pp
Operating margin-1,071.5%-90.6pp
Net margin-1,350.7%-35.3pp
FCF margin-864.7%-194pp

Returns & leverage

See full
Return on equity-228.2%-11.6pp
Debt / equity0.2×
Current ratio10×0.0×

Where this comes from

Reported directly by uniQure in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The source filing: uniQure’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 7:17 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-087815
Line itemJune 30, 2026December 31, 2025
Current assets
Cash and cash equivalents$413,027$80,240
Current investment securities397,308542,301
Accounts receivable5,7785,863
Prepaid expenses10,24520,506
Other current assets and receivables7,9117,076
Total current assets834,269655,986
Non-current assets

Item 1.Financial Statements

FAQ

What is uniQure's cash & equivalents?
uniQure (QURE) reported cash & equivalents of $413.03M in Q2 2026.
How has uniQure's cash & equivalents changed year-over-year?
uniQure's cash & equivalents increased by 62.8% year-over-year, from $253.78M to $413.03M.
What is the long-term trend for uniQure's cash & equivalents?
Over 5 years (2020 to 2025), uniQure's cash & equivalents has grown at a -20.0% compound annual growth rate (CAGR), from $244.93M to $80.24M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about uniQure's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude